Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
What's going on with polio, monkeypox, and COVID-19
The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?
FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age
Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.
What Omicron could mean for the pandemic
Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention
Ramilo, a clesrovimab clinical trial investigator, breaks down the recent FDA approval for the newest monoclonal antibody to protect against RSV disease in infants.
FDA approves clesrovimab to protect infants during first RSV season
The BLA for clesrovimab was based on results demonstrated in the phase 2b/3 CLEVER trial among healthy pre-term and full-term infants.
